Vaccinia virus intermediate stage transcription is complemented by Ras-GTPase-activating protein SH3 domain-binding protein (G3BP) and cytoplasmic activation/proliferation-associated protein (p137) individually or as a heterodimer
about
Systemic delivery of oncolytic viruses: hopes and hurdlesDistinct structural features of caprin-1 mediate its interaction with G3BP-1 and its induction of phosphorylation of eukaryotic translation initiation factor 2alpha, entry to cytoplasmic stress granules, and selective interaction with a subset of mRWho Regulates Whom? An Overview of RNA Granules and Viral InfectionsCrystal structures of the human G3BP1 NTF2-like domain visualize FxFG Nup repeat specificityPoxvirus tropismDrosophila S2 cells are non-permissive for vaccinia virus DNA replication following entry via low pH-dependent endocytosis and early transcriptionInhibition of type I interferon induction and signalling by mosquito-borne flavivirusesG3BP1, G3BP2 and CAPRIN1 are required for translation of interferon stimulated mRNAs and are targeted by a dengue virus non-coding RNA.Colocalization of transcription and translation within cytoplasmic poxvirus factories coordinates viral expression and subjugates host functions.Microtubule-dependent association of AKAP350A and CCAR1 with RNA stress granules.Correlates between host and viral transcriptional program associated with different oncolytic vaccinia virus isolates.Oncolytic viral purging of leukemic hematopoietic stem and progenitor cells with Myxoma virusRNA granule assembly and disassembly modulated by nuclear factor associated with double-stranded RNA 2 and nuclear factor 45Control of fetal growth and neonatal survival by the RasGAP-associated endoribonuclease G3BP.Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans.Hepatitis C virus co-opts Ras-GTPase-activating protein-binding protein 1 for its genome replication.Sequential therapy with JX-594, a targeted oncolytic poxvirus, followed by sorafenib in hepatocellular carcinoma: preclinical and clinical demonstration of combination efficacyStress granules regulate double-stranded RNA-dependent protein kinase activation through a complex containing G3BP1 and Caprin1.An overview of the vaccinia virus infectome: a survey of the proteins of the poxvirus-infected cellTreating tumors with a vaccinia virus expressing IFNβ illustrates the complex relationships between oncolytic ability and immunogenicity.Poxvirus DNA primaseEukaryotic translation initiation factor 4F architectural alterations accompany translation initiation factor redistribution in poxvirus-infected cellsDiversion of stress granules and P-bodies during viral infection.Cytoplasmic RNA Granules and Viral Infection.P bodies, stress granules, and viral life cycles.Vaccinia virus, a promising new therapeutic agent for pancreatic cancer.Cascade regulation of vaccinia virus gene expression is modulated by multistage promoters.A proteomic perspective of Sirtuin 6 (SIRT6) phosphorylation and interactions and their dependence on its catalytic activity.Oncolytic vaccinia virotherapy for endometrial cancerRegulation of stress granules in virus systemsReplicating poxviruses for human cancer therapy.Biochemical analysis of the multifunctional vaccinia mRNA capping enzyme encoded by a temperature sensitive virus mutant.The emerging therapeutic potential of the oncolytic immunotherapeutic Pexa-Vec (JX-594)Barrier to autointegration factor (BAF) inhibits vaccinia virus intermediate transcription in the absence of the viral B1 kinase.Formation of antiviral cytoplasmic granules during orthopoxvirus infection.Vaccinia virus regulates expression of p21WAF1/Cip1 in A431 cells.Identification of Vaccinia Virus Replisome and Transcriptome Proteins by Isolation of Proteins on Nascent DNA Coupled with Mass Spectrometry.Tracking and elucidating alphavirus-host protein interactions.Vaccinia virus intermediate and late promoter elements are targeted by the TATA-binding protein.Purification, crystallization and preliminary X-ray diffraction of the G3BP1 NTF2-like domain.
P2860
Q21284969-C933F8D7-3D49-4D3E-8EBC-CD9FAE0E0B74Q24681390-F497F9F7-8670-48E5-83D5-06F3F1520A50Q26700102-907A3148-0F1D-42A5-A886-CEE14648C920Q27680858-8000FBEC-4532-4FC0-949F-361464787E8BQ28237434-DA788B4C-EEAA-4C98-A0F5-35B9A29BF494Q28477161-AA91A9E4-F189-4A17-B0D7-C8BD9CB7A89AQ28950689-1BED2C20-6E59-4BEC-8B73-FD1A16D09937Q30411973-B3ED73B3-556B-45FB-B7FD-29451DE89870Q30480693-FDBCAE19-E3CC-4BB0-9419-74EBB315859BQ30492188-13E653EF-FD2F-461D-819D-E00DC56542FCQ33587040-29FF3CDC-9C78-43FD-85A7-2FAD6A4284A7Q33895494-88C3CE70-70E2-461E-9F9B-0120A9F2FD25Q33947271-5C3F851D-DCFE-4F02-B53F-FB2B84A67D84Q34097141-336E031D-CFEC-44C4-A17F-C4A786E0FB74Q34212910-D0BD8775-667D-4DA3-B258-7062EECBC839Q35077661-50295CE9-0D34-4ACB-9518-E4370C2F19DEQ35086690-3353AAC4-A687-44C9-9894-1BCB103342F9Q35677453-A346FDCA-FAF8-4FC0-A735-CD5913D6A1CFQ35689619-2C272A00-369B-4BBD-992B-62C95B6B99EFQ35876239-96AB539E-35B6-4C31-900A-5553F449DF62Q36276981-1B944DC2-0A3B-42E5-AC5C-BBEBC5145F0CQ36540315-6E1A0644-F5E4-4E69-A911-1EA1C97A03E4Q36727541-9407DB08-422D-4F77-B253-A7803DF93F10Q36901471-69227F8E-6278-4593-992A-61B7F7F2C10CQ37136680-2BF887EA-57EB-406C-B28D-D7BED2517BD0Q37158473-2C3078D7-4516-4283-9279-710FC48F14E6Q37341397-46763DAF-8E18-470F-9020-B6B9C7C3E17EQ37428821-F365D240-080B-4513-AAD7-E42FC0CF79D4Q37688850-589FCDEC-1AB8-445B-9187-479EFA125E02Q37992291-CE659097-C0EC-4361-9FCF-1F40F4D4C2BEQ38407351-62708773-066B-431C-9857-FE97A80639A1Q38825548-6F1E031F-6DF7-431E-82C8-B43F097B28AAQ38924552-6C630DBF-E2B6-4E97-AF7C-7F9B1680416DQ39119770-25A3982D-7EEA-4E27-9BB3-CB4302EA5312Q39621474-1D3ABED3-7D6E-41B7-9ACC-F192FB213BC1Q39698568-DC012A8D-16B9-434F-86C3-087EA572F0C4Q40107018-59DE5E0C-3D09-4CBF-9758-C3BA9717E378Q40245922-4851AB70-F228-4CE8-88F3-74CF1C99DBD7Q41494215-61D0EA49-F09F-49FD-9199-6043DEB065F8Q41987466-19411CD8-7F3C-48FE-8870-81E652FB9C96
P2860
Vaccinia virus intermediate stage transcription is complemented by Ras-GTPase-activating protein SH3 domain-binding protein (G3BP) and cytoplasmic activation/proliferation-associated protein (p137) individually or as a heterodimer
description
2004 nî lūn-bûn
@nan
2004 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Vaccinia virus intermediate st ...... dividually or as a heterodimer
@ast
Vaccinia virus intermediate st ...... dividually or as a heterodimer
@en
Vaccinia virus intermediate st ...... dividually or as a heterodimer
@nl
type
label
Vaccinia virus intermediate st ...... dividually or as a heterodimer
@ast
Vaccinia virus intermediate st ...... dividually or as a heterodimer
@en
Vaccinia virus intermediate st ...... dividually or as a heterodimer
@nl
prefLabel
Vaccinia virus intermediate st ...... dividually or as a heterodimer
@ast
Vaccinia virus intermediate st ...... dividually or as a heterodimer
@en
Vaccinia virus intermediate st ...... dividually or as a heterodimer
@nl
P2860
P3181
P356
P1476
Vaccinia virus intermediate st ...... dividually or as a heterodimer
@en
P2093
George C Katsafanas
P2860
P304
P3181
P356
10.1074/JBC.M411033200
P407
P50
P577
2004-12-10T00:00:00Z